Phase I, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adults of a DNA Plasmid Vaccine for H5 Avian Influenza (VGX-3400X) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP).

Trial Profile

Phase I, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adults of a DNA Plasmid Vaccine for H5 Avian Influenza (VGX-3400X) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP).

Completed
Phase of Trial: Phase I

Latest Information Update: 21 May 2012

At a glance

  • Drugs VGX 3400 (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions
  • Most Recent Events

    • 21 May 2012 Actual end date (1 Nov 2011) added as reported by ClinicalTrials.gov. (Parent trial: NCT01142362)
    • 16 May 2012 Status changed from active, no longer recruiting to completed, according to an Inovio Pharmaceuticals media release.
    • 30 Mar 2012 Planned end date changed from 1 Nov 2011 to 1 May 2012 as reported by ClinicalTrials.gov (Parent trial: NCT01142362).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top